Get the Stockscreener App
1,063.56
1.99%
-21.63
After Hours:
1064.00
0.44
+0.04%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,063.56, with a volume of 2.51M.
It is down -1.99% in the last 24 hours and up +8.28% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,085.19
Open:
$1086.825
24h Volume:
2.51M
Relative Volume:
0.73
Market Cap:
$951.91B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
52.60
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-1.56%
1M Performance:
+8.28%
6M Performance:
+35.15%
1Y Performance:
+35.10%
1-Day Range:
$1,063.03
$1,104.52
1-Week Range:
$1,033.38
$1,133.95
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,063.56 | 971.27B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
204.39 | 495.71B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
220.08 | 396.12B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
110.53 | 275.48B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
NVS
Novartis Ag Adr
|
141.54 | 271.43B | 54.45B | 14.42B | 17.15B | 7.333 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand - GlobeNewswire Inc.
Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences - Finviz
Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY - TechStock²
2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market - CNBC
Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in - TechStock²
Bull of the Day: Eli Lilly (LLY) - The Globe and Mail
Boston-based Aktis, backed by Eli Lilly, jumps 24% after $318 million US IPO - The Boston Globe
Eli Lilly-Backed Aktis Jumps 24% After $318 Million US IPO - Bloomberg.com
Chai Discovery’s commercial strategy takes shape with Lilly deal - FirstWord
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences - FinancialContent
Eli Lilly and Company Stock (LLY) Opinions on Obesity Drug Partnership and Acquisition Talks - Quiver Quantitative
Lilly partner Aktis surges on trading debut (AKTS:NASDAQ) - Seeking Alpha
Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery - 01net
Eli Lilly in pact with Schrödinger, Revvity for AI-driven drug discovery - MSN
Zepbound And Taltz Combo Bolsters Lilly’s Co-Morbidity Plans - Citeline News & Insights
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY) - FinancialContent
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models - PharmiWeb.com
Aktis breaks IPO ice with $318M Lilly-led offering - FirstWord
Here's What UBS Thinks About Eli Lilly and Company (LLY) - Finviz
Here’s What UBS Thinks About Eli Lilly and Company (LLY) - Yahoo Finance
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software - Reuters
Chai Discovery announces collaboration with Eli Lilly and Company to accelerate biologics discovery - MarketScreener
Revvity, Inc. Collaborates with Eli Lilly and Company to Expand Access to Ai Drug Discovery Models - MarketScreener
Lilly joins Schrödinger, Revvity for AI drug discovery (update) - Seeking Alpha
Tax agreement for $6.5B Eli Lilly plant is official, including 6-figure average annual wages - The Business Journals
Eli Lilly joins Schrödinger in AI drug discovery (SDGR:NASDAQ) - Seeking Alpha
Rx Rundown: Insilico Medicine, Sanofi, Eli Lilly and more - Medical Marketing and Media
Eli Lilly (LLY) Partners with Schrodinger to Enhance Drug Discov - GuruFocus
Big pharma opens its AI drug tools to smaller biotechs in new deal - Stock Titan
Schrödinger partners with Lilly TuneLab to enhance drug discovery By Investing.com - Investing.com Australia
Exclusive: With new AI deal, Eli Lilly and Chai Discovery kick off a 'year of deployment' in pharma - Endpoints News
Eli Lilly: Incretin-Driven Above-Peer Growth Justifies Premium Valuation and Supports Overweight Rating - TipRanks
Eli Lilly vs. Novo Nordisk: Which Is the Best Stock to Buy Today? - Morningstar
Eli Lilly and JD.com have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Lilly To Buy Ventyx Biosciences For $1.2 Billion To Expand Oral Inflammation Pipeline - Pulse 2.0
Eli Lilly-Backed Aktis Oncology Gets $317.7 Million in US IPO - Bloomberg.com
Major Eli Lilly Stakeholder Makes Bold Move With Massive Share Sale - TipRanks
Lilly Endowment sells Eli Lilly & Co (LLY) stock worth $322m - Investing.com Nigeria
Lilly Endowment sells Eli Lilly & Co (LLY) stock worth $322m By Investing.com - Investing.com South Africa
Ventyx’s NLRP3 inhibitors best in class? Lilly offers $1.2B - BioWorld MedTech
Pharmacy XD Launches Nationally Licensed Direct-to-Patient Mail Order Pharmacy and Distribution Platform - Benzinga
2 Firms Guide Eli Lilly's $1.2B Ventyx Biosciences Acquisition - Law360
Lilly Endowment Sells Over $322 Million of Eli Lilly & Co Common Stock - TradingView — Track All Markets
Lilly Endowment (LLY 10% owner) discloses Eli Lilly share sales around $1,100 - Stock Titan
Eli Lilly's (LLY) Taltz and Zepbound Show Positive Results in Ps - GuruFocus
Eli Lilly (LLY) Reports Positive Results with Psoriatic Arthritis Treatment - GuruFocus
Lilly trial finds psoriatric arthritis, weight improvement in Taltz + Zepbound combo - Seeking Alpha
Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial - Reuters
Eli Lilly (LLY) Poised for Aggressive M&A Amid Biopharma Surge - GuruFocus
Lilly’s taltz and zepbound combination shows efficacy in psoriatic arthritis - Investing.com
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight | Eli Lilly and Company - Eli Lilly
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):